Bringing prosocial values to translational, disease-specific stem cell research

BMC Medical Ethics

Reuben G Sass¹ 

[1] Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-4976, USA

关键词: Behavioral economics;    Moral philosophy;    Patient advocacy;    Cultural studies;    Communitarianism;    Stem cells;   

Others  :  799576
DOI  :  10.1186/1472-6939-15-16

 received in 2013-11-28, accepted in 2014-02-21,  发布年份 2014

【 摘 要 】

Background

Disease-specific stem cell therapies, created from induced pluripotent stem cell lines containing the genetic defects responsible for a particular disease, have the potential to revolutionize the treatment of refractory chronic diseases. Given their capacity to differentiate into any human cell type, these cell lines might be reprogrammed to correct a disease-causing genetic defect in any tissue or organ, in addition to offering a more clinically realistic model for testing new drugs and studying disease mechanisms. Clinical translation of these therapies provides an opportunity to design a more systematic, accessible and patient-influenced model for the delivery of medically innovative treatments to chronically ill patients.

Discussion

I focus on disease-specific cell therapies because the types of patients who would benefit from them have congenital, severe, high-maintenance chronic conditions. They accordingly have a very strong claim for medical need and therapeutic intervention, must interact regularly with health providers, and so have the greatest stake in influencing, at a systemic level, the way their care is delivered. Given such patients’ shared, aggregate needs for societal support and access to medical innovation, they constitute “patient communities”. To reify the relevance of patient communities within a clinical context, I propose competitive grants or “prizes” to spur innovation in delivery of care, promoting “prosocial” values of transparency, equity, patient empowerment, and patient-provider and inter-institutional collaboration. As facilitators of participant-driven advocacy for health and quality of life-improving measures, patient communities may be synergistic with the broad-based, geo-culturally embedded public health networks typically referred to as “communities” in the public health literature.

Summary

Prosocial values acquire a strong ethical justification based on shared need, and can be clearly defined as grant criteria, when applied to patients such as those who will benefit from disease-specific stem cell treatments. Within this context, prosociality aims not just to expand patients’ treatment choices, but also their opportunities to take a more active role in the management of their own care and contribute towards shared goals through better-informed advocacy. Accordingly, prosociality promotes relational autonomy as well as other basic bioethical principles, including beneficence and a holistic, relational conception of human dignity.

【 授权许可】

   
2014 Sass; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Waldby C, Mitchell R: Tissue Economies: Blood, Organs, and Cell lines in Late Capitalism. Durham: Duke University Press; 2006.
• [2]Cooper M: Life as Surplus: Biotechnology and Capitalism in the Neoliberal Era. Seattle: University of Washington Press; 2008.
• [3]Sass RG: Towards a more stable blood supply: charitable incentives, donation rates, and the experience of September 11. Am J Bioeth 2013, 13:38-45.
• [4]NIH stem cell research funding, FY 2002–2013. [http://stemcells.nih.gov/research/funding/pages/Funding.aspx webcite]
• [5]Raya Á, Rodríguez-Pizà I, Guenechea G, Vassena R, Navarro S, José Barrero M, Consiglio A, Castellà M, Río P, Sleep E, González F, Tiscornia G, Garreta E, Aasen T, Veiga A, Verma IM, Surrallés J, Bueren J, Izpisúa Belmonte JC: Disease-corrected haematopoietic progenitors from Fanconi Anaemia induced pluripotent stem cells. Nat 2009, 460:53-59.
• [6]Ebert AD, Yu J, Rose FF, Mattis VB, Lorson CL, Thomson JA, Svendsen CN: Induced pluripotent stem cells from a spinal muscular atrophy patient. Nat 2009, 457:277-280.
• [7]International Society for Stem-Cell Research: Guidelines for the clinical translation of stem cells. [http://www.isscr.org/docs/guidelines/isscrglclinicaltrans.pdf webcite]
• [8]Wei M: Should prizes replace patents? A critique of the Medical Innovation Prize Act of 2005. BU J Sci Tech L 2007, 13(1):25-46.
• [9]Foster C: Human Dignity in Bioethics and Law. Portland: Hart Publishing; 2011.
• [10]Cost of bone marrow transplant. [http://www.nbmtlink.org/resources_support/rg/rg_costs.htm webcite]
• [11]Bodenheimer T, Grumbach K: Understanding Health Policy. 6th edition. New York: McGraw-Hill; 2012.
• [12]Berwick DM, Nolan TW, Whittington J: The triple aim: care, health, and cost. Health Aff 2008, 27(3):759-769.
• [13]Mitchell R: Access, entanglement and prosociality. Am J Bioeth 2013, 13(6):49-51.
• [14]Sandel M: The procedural republic and the unencumbered self. In Communitarianism and Individualism. Edited by Avineri S, de Shalit A. New York: Oxford University Press; 1992:12-29.
• [15]Wiggins D: Needs, Values, Truth. New York: Oxford University Press; 1998.
• [16]Spinal muscular atrophy. [http://www.childrenshospital.org/az/Site1061/mainpageS1061P0.html webcite]
• [17]Park I, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ: Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
• [18]United States patient protection and affordable care act. [http://www.gpo.gov/fdsys/pkg/BILLS-111hr3590enr/pdf/BILLS-111hr3590enr.pdf webcite]
• [19]Fischer A: Severe combined immunodeficiencies. Clin Exp Immunol 2000, 122:143-149.
• [20]Sheehy J: Advocates deserve room at the decision-making table. Nat Med 2010, 16:1070.
• [21]Cohen S: Nudging and informed consent. Am J Bioeth 2013, 13(6):3-11.
• [22]Taylor C: Atomism. In Communitarianism and Individualism. Edited by Avineri S, de Shalit A. New York: Oxford University Press; 1992:29-51.
• [23]Ladd J: The idea of community, an ethical exploration, part I: the search for an elusive concept. J Value Inq 1998, 32:5-24.
• [24]Minkler M, Blackwell AG, Thompson M, Tamir H: Community-based participatory research: implications for public health funding. Am J Pub Health 2003, 93:1210-1213.
• [25]Entwistle VA, Watt IS: Treating patients as persons: a capabilities approach to delivery of person-centered care. Am J Bioeth 2013, 13(8):29-39.
• [26]Levinas E: Otherwise than Being, or Beyond Essence. Dordrecht: Kluwer Academic Publishers; 1981.
• [27]Butler J: Giving an Account of Oneself. New York: Fordham University Press; 2005.